Montelukast vs Rituximab

## Montelukast vs Rituximab: Overview

This comparison examines the pharmacological differences between **Montelukast** and **Rituximab**.

## Mechanism of Action

**Montelukast**: Selective leukotriene D4 receptor antagonist.

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Montelukast — 2.7-5.5 hours; Rituximab — 22 days.

## Chemical Properties

**Molecular Formula**: Montelukast — C35H36ClNO3S; Rituximab — N/A.

**Molecular Weight**: Montelukast — 586.1800 g/mol; Rituximab — N/A.

**Type**: Montelukast — Small molecule; Rituximab — Antibody.